X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3646) 3646
Book Review (909) 909
Publication (321) 321
Book Chapter (36) 36
Conference Proceeding (12) 12
Dissertation (10) 10
Reference (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2603) 2603
glp-1 (1754) 1754
humans (1720) 1720
glucagon-like peptide-1 (1463) 1463
animals (1379) 1379
endocrinology & metabolism (1375) 1375
type 2 diabetes (1213) 1213
male (1128) 1128
diabetes (1100) 1100
glucagon (953) 953
diabetes mellitus, type 2 - drug therapy (897) 897
glucose (819) 819
liraglutide (798) 798
insulin (786) 786
female (652) 652
pharmacology & pharmacy (633) 633
hypoglycemic agents - therapeutic use (628) 628
peptides (625) 625
mice (610) 610
rats (535) 535
exenatide (533) 533
obesity (530) 530
glucagon-like peptide-1 receptor (488) 488
glycemic control (481) 481
diabetes mellitus (464) 464
middle aged (449) 449
glp-1 receptor agonists (431) 431
analysis (430) 430
glp-1 receptor (419) 419
glucagon-like peptide 1 (415) 415
exendin-4 (412) 412
glucagon-like peptide 1 - metabolism (388) 388
dextrose (376) 376
internal medicine (370) 370
blood glucose - metabolism (367) 367
hypoglycemic agents - pharmacology (354) 354
glp-1 receptor agonist (353) 353
glucagon-like peptide 1 - analogs & derivatives (342) 342
peptides - pharmacology (335) 335
adult (334) 334
medicine & public health (316) 316
double-blind (315) 315
biochemistry & molecular biology (313) 313
diabetes mellitus, type 2 - blood (310) 310
metformin (304) 304
type-2 diabetes-mellitus (303) 303
insulin - metabolism (302) 302
digestive, oral, and skin physiology (294) 294
secretion (294) 294
blood glucose - drug effects (293) 293
treatment outcome (293) 293
rodents (288) 288
hypoglycemic agents - administration & dosage (287) 287
physiological aspects (285) 285
diabetes therapy (283) 283
aged (282) 282
endocrine system (282) 282
diabetes mellitus, type 2 - metabolism (280) 280
research (279) 279
care and treatment (275) 275
incretin (275) 275
hypoglycemic agents (274) 274
glucagon-like peptide 1 - pharmacology (265) 265
glucagon-like peptide 1 - therapeutic use (265) 265
receptors, glucagon - agonists (262) 262
venoms - pharmacology (260) 260
open-label (256) 256
safety (254) 254
body weight (252) 252
drug therapy (250) 250
insulin secretion (246) 246
hypoglycemic agents - adverse effects (245) 245
glucagon-like peptide-1 receptor - agonists (241) 241
expression (240) 240
health aspects (240) 240
hormones, hormone substitutes, and hormone antagonists (240) 240
insulin resistance (234) 234
insulin-secretion (234) 234
clinical trials (232) 232
beta-cell function (230) 230
food-intake (228) 228
glucose metabolism (228) 228
mice, inbred c57bl (227) 227
peptides - therapeutic use (225) 225
receptor (225) 225
hyperglycemia (223) 223
receptors, glucagon - metabolism (221) 221
abridged index medicus (212) 212
type 2 diabetes mellitus (208) 208
efficacy (204) 204
metabolism (202) 202
article (200) 200
neurosciences (197) 197
risk factors (196) 196
physiology (194) 194
hypoglycemia (193) 193
rats, sprague-dawley (191) 191
endocrinology (190) 190
medicine, research & experimental (187) 187
activation (180) 180
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3557) 3557
German (44) 44
French (25) 25
Spanish (24) 24
Japanese (12) 12
Korean (6) 6
Czech (4) 4
Polish (2) 2
Russian (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0132744 - e0132744
Recently, a number of studies have demonstrated the potential beneficial role for novel antidiabetic GLP-1 receptor agonists (GLP-1RAs) in the skeleton... 
PROGENITORS | IN-VITRO | MARROW | RESORPTION | OSTEOBLAST FORMATION | EXENDIN-4 | MULTIDISCIPLINARY SCIENCES | MICE | DIFFERENTIATION | GLP-1 RECEPTOR | MESENCHYMAL STEM-CELLS | Mesenchymal Stromal Cells - drug effects | Bone and Bones - physiology | Osteoporosis - prevention & control | Ovariectomy | Rats, Wistar | Adipogenesis - drug effects | Humans | Osteoblasts - drug effects | Osteogenesis - drug effects | Cells, Cultured | Diabetes Mellitus - metabolism | Rats | Male | PPAR gamma - metabolism | Bone and Bones - drug effects | Bone Density - drug effects | Mesenchymal Stromal Cells - cytology | Anabolic Agents - pharmacology | Animals | Osteoporosis - pathology | Liraglutide - pharmacology | Female | Osteoporosis - physiopathology | Glucagon-Like Peptide-1 Receptor - agonists | Osteoporosis | Glucagon | Physiological aspects | Bones | Hypoglycemic agents | Diabetes | Density | Alkaline phosphatase | Peptides | Menopause | Hormones | Adipocytes | Bone surgery | Biomedical materials | Computed tomography | Rodents | Surgery | Bone marrow | Biocompatibility | Skeleton | Glucagon-like peptide 1 | Cbfa-1 protein | Vertebrae | Diabetes mellitus | Gene expression | Metabolism | Insulin | Medicine | Osteoblastogenesis | Bone mass | Stromal cells | Collagen | Stem cells | Bone mineral density | Laboratory animals | Endocrinology | Metabolic disorders | Index Medicus
Journal Article
Diabetologia, ISSN 0012-186X, 4/2011, Volume 54, Issue 4, pp. 965 - 978
Glucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1... 
Human Physiology | Metabolic Diseases | Internal Medicine | Nuclear factor-κB | Exendin-4 | Medicine & Public Health | Intercellular adhesion molecule-1 | Type 1 diabetic rats | Anti-inflammatory effect | Diabetic nephropathy | GLP-1 receptor agonist | Glomerular endothelial cells | Macrophage | Nuclear factor-kappa B | KIDNEY-DISEASE | HEALTHY-SUBJECTS | NEPHROPATHY | ADHESION | GROWTH-FACTOR-BETA | ENDOTHELIAL-CELLS | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | MESANGIAL CELLS | MICE | NF-KAPPA-B | Collagen Type IV - metabolism | Receptors, Glucagon - agonists | Cell Line | Humans | Rats | Receptors, Glucagon - metabolism | Male | NF-kappa B - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Rats, Sprague-Dawley | Blotting, Western | Diabetes Mellitus, Type 1 - drug therapy | Peptides - pharmacology | Blood Glucose - drug effects | Tumor Necrosis Factor-alpha - pharmacology | Intercellular Adhesion Molecule-1 - metabolism | Animals | Glucagon-Like Peptide-1 Receptor | Fluorescent Antibody Technique | Venoms - therapeutic use | Cell Line, Tumor | Venoms - pharmacology | Diabetic Nephropathies - prevention & control | Peptides - therapeutic use | Medical colleges | Pancreatic beta cells | Peptides | Anti-inflammatory drugs | Type 1 diabetes | Blood sugar | Collagen | Body weight | Diabetic nephropathies | Albumin | Macrophages | Endothelium | Prevention | Glucose metabolism | Glucagon | Streptozocin | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2012, Volume 14, Issue 10, pp. 910 - 917
Aims: To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal... 
basal insulin | GLP | type 2 diabetes | Asian patients | lixisenatide | Type 2 diabetes | Basal insulin | GLP-1 | Lixisenatide | METFORMIN | GLYCEMIC CONTROL | EFFICACY | SAFETY | EXENATIDE | PEPTIDE-1 ANALOG LIRAGLUTIDE | HYPERGLYCEMIA | ENDOCRINOLOGY & METABOLISM | JAPANESE PATIENTS | WEIGHT | GLIBENCLAMIDE | Japan - epidemiology | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Sulfonylurea Compounds - pharmacology | Philippines - epidemiology | Postprandial Period | Aged, 80 and over | Adult | Female | Hypoglycemia - blood | Sulfonylurea Compounds - administration & dosage | Drug Therapy, Combination | Republic of Korea - epidemiology | Body Mass Index | Insulin - pharmacology | Double-Blind Method | Drug Administration Schedule | Blood Glucose | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Asian Continental Ancestry Group | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Taiwan - epidemiology | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Clinical trials | Blood sugar | Insulin | Diabetes therapy | Index Medicus | Original
Journal Article
Brain Research, ISSN 0006-8993, 01/2018, Volume 1678, pp. 64 - 74
Journal Article
Journal Article
Experimental and Molecular Pathology, ISSN 0014-4800, 04/2019, Volume 107, pp. 124 - 128
Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, is an antidiabetic drug. It has been shown to improve the Psoriasis Area and Severity Index (PASI) in... 
AMPK | Inflammation | GLP-1 | Psoriasis | PEPTIDE-1 RECEPTOR | CELLS | ENDOTHELIAL DYSFUNCTION | PATHOLOGY | PSORIASIS-VULGARIS | IMPROVEMENT | INHIBITORS | STRESS | NF-KAPPA-B | EXPRESSION | SEVERITY | Type 2 diabetes | Peptides | Dermatology | Formulae, receipts, prescriptions | Dermatologic agents | Skin | Macrophages | Liraglutide | Index Medicus
Journal Article
Endocrinology, ISSN 0013-7227, 04/2010, Volume 151, Issue 4, pp. 1473 - 1486
Journal Article